{"text": "Reduction of <extra_id_0> tumour necrosis factor alpha <extra_id_2> Protein <extra_id_1> expression and signalling in peripheral blood mononuclear cells from patients with thalassaemia or sickle cell anaemia upon treatment with desferrioxamine .", "event": "<extra_id_0> <extra_id_0> Negative_regulation Reduction <extra_id_0> Theme expression <extra_id_1> <extra_id_1> <extra_id_0> Gene_expression expression <extra_id_0> Theme tumour necrosis factor alpha <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "Recent evidence indicates that the rate of progression of the HIV-1 disease is significantly reduced in thalassaemia major patients upon treatment with high doses of desferrioxamine ( DFX ) .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "The authors have previously demonstrated that in vitro exposure of mononuclear cells to DFX decreases the bioavailability of <extra_id_0> tumour necrosis factor alpha <extra_id_2> Protein <extra_id_1> ( <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> ) which has a stimulatory effect on HIV-1 replication .", "event": "<extra_id_0> <extra_id_0> Negative_regulation decreases <extra_id_0> Theme TNF-alpha <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "In this study , therefore , <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> bioavailability from mononuclear cells isolated from 10 patients with thalassaemia or sickle cell anaemia given DFX as compared to 10 untreated subjects has been evaluated .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Evidence is presented showing that DFX treatment reduces <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> bioavailability ( P < 0.05 ) by inhibiting its steady state ( P < 0.05 ) and by enhancing its inactivation through binding to soluble <extra_id_0> TNF-alpha receptor type II <extra_id_2> Protein <extra_id_1> ( P < 0.05 ) .", "event": "<extra_id_0> <extra_id_0> Negative_regulation reduces <extra_id_0> Theme TNF-alpha <extra_id_1> <extra_id_1> <extra_id_0> Positive_regulation enhancing <extra_id_0> Theme inactivation <extra_id_1> <extra_id_0> Cause binding <extra_id_1> <extra_id_1> <extra_id_0> Negative_regulation inactivation <extra_id_0> Theme TNF-alpha receptor type II <extra_id_1> <extra_id_1> <extra_id_0> Binding binding <extra_id_0> Theme TNF-alpha receptor type II <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "We also show that DFX treatment limits the in vivo activation of NF-kappaB , a transcription factor involved in both <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> gene transcription and <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> signalling ( P < 0.005 ) .", "event": "<extra_id_0> <extra_id_0> Positive_regulation involved <extra_id_0> Theme transcription <extra_id_1> <extra_id_1> <extra_id_0> Transcription transcription <extra_id_0> Theme TNF-alpha <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "We conclude that <extra_id_0> TNF-alpha <extra_id_2> Protein <extra_id_1> bioavailability and signalling are impaired in patients upon DFX treatment .", "event": "<extra_id_0> <extra_id_0> Negative_regulation impaired <extra_id_0> Theme TNF-alpha <extra_id_1> <extra_id_1> <extra_id_1>"}
{"text": "This mechanism may contribute to delayed progression of the HIV-1 infection in vivo .", "event": "<extra_id_0> <extra_id_1>"}
{"text": "Copyright 1999 Academic Press .", "event": "<extra_id_0> <extra_id_1>"}
